BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) released its quarterly earnings results on Wednesday. The biotechnology company reported $0.72 EPS for the quarter, beating analysts' consensus estimates of $0.54 by $0.18, Zacks reports. BioMarin Pharmaceutical had a return on equity of 10.10% and a net margin of 14.96%. The company had revenue of $747.31 million during the quarter, compared to analysts' expectations of $711.05 million. BioMarin Pharmaceutical updated its FY 2025 guidance to 4.200-4.400 EPS.
BioMarin Pharmaceutical Stock Performance
BioMarin Pharmaceutical stock traded down $0.48 during midday trading on Friday, hitting $68.25. 2,348,882 shares of the company were exchanged, compared to its average volume of 1,616,799. The firm has a market capitalization of $13.01 billion, a PE ratio of 31.02, a price-to-earnings-growth ratio of 0.58 and a beta of 0.28. BioMarin Pharmaceutical has a fifty-two week low of $60.63 and a fifty-two week high of $94.85. The business has a fifty day simple moving average of $64.84 and a two-hundred day simple moving average of $71.05. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 4.27.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on the company. JPMorgan Chase & Co. decreased their price target on BioMarin Pharmaceutical from $110.00 to $109.00 and set an "overweight" rating for the company in a research note on Wednesday, October 30th. Evercore ISI decreased their price target on BioMarin Pharmaceutical from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Wednesday, October 30th. Wolfe Research initiated coverage on BioMarin Pharmaceutical in a research note on Friday, November 15th. They issued an "outperform" rating and a $95.00 price target for the company. William Blair lowered BioMarin Pharmaceutical from an "outperform" rating to a "market perform" rating in a report on Wednesday, October 30th. Finally, StockNews.com raised BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Tuesday, February 11th. Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $93.81.
Read Our Latest Research Report on BioMarin Pharmaceutical
BioMarin Pharmaceutical Company Profile
(
Get Free Report)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Featured Articles
Before you consider BioMarin Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.
While BioMarin Pharmaceutical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
